Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]
Discontinued
Reference number: GID-TA10737
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal.
The company that market avatrombopag has advised NICE that they are currently not pursuing a licence in the UK for this product for this indication. In light of this information, NICE will not be progressing with the scoping exercise. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience.